Male Hypogonadism Monitoring Schedule: When to Test and What to Track on TRT

Why a Fixed Monitoring Schedule Matters

Testosterone replacement therapy is not a set-and-forget prescription. The Endocrine Society's 2018 clinical practice guideline calls for structured, timed lab evaluations because TRT affects hematologic, cardiovascular, hepatic, and prostatic endpoints simultaneously. Missing a single checkpoint can allow a correctable problem (polycythemia, rising PSA, suppressed spermatogenesis) to progress silently.

A 2020 retrospective of 4,834 men on TRT at Veterans Affairs facilities found that only 58.3% received guideline-concordant monitoring within the first year. Men who skipped the 3-month hematocrit check were 2.1 times more likely to present with hematocrit above 54% at their next visit. That number underscores a simple point: the schedule itself is a safety intervention.

The American Urological Association's 2018 guideline reinforces this timeline and adds that clinicians should evaluate symptom response with a validated questionnaire (qADAM or AMS) at each visit, not just rely on lab numbers. Symptoms and serum levels do not always move in parallel. A man can have a trough testosterone of 500 ng/dL and still report persistent fatigue if his sleep apnea remains untreated.

Confirming the Diagnosis: The Pre-TRT Workup

Before any monitoring schedule begins, the diagnosis itself must be airtight. The Endocrine Society requires two separate morning serum total testosterone measurements below 300 ng/dL, drawn between 7:00 and 10:00 AM when diurnal secretion peaks, combined with at least one consistent symptom such as low libido, erectile dysfunction, fatigue, or loss of lean mass.

Free testosterone should be measured or calculated when total T is borderline (between 200 and 400 ng/dL) because sex hormone-binding globulin (SHBG) can obscure the clinical picture. The CDC-harmonized lower cutoff of 264 ng/dL, established through the Harmonized Reference Ranges project, is used by some labs and may flag fewer men than the 300 ng/dL threshold.

LH and FSH distinguish primary (testicular) from secondary (pituitary/hypothalamic) hypogonadism. An elevated LH above 9.4 IU/L with low T points to primary failure. Normal or low LH with low T triggers additional workup: prolactin, iron saturation (to rule out hemochromatosis), pituitary MRI if prolactin is elevated, and assessment for obstructive sleep apnea, opioid use, or obesity. This etiology workup must happen before the first testosterone dose because exogenous T will suppress LH/FSH within weeks and mask the underlying cause [1].

Baseline Labs: What to Draw Before the First Dose

The baseline panel serves two purposes: it establishes pre-treatment safety values and creates a reference against which all future labs are compared. The Endocrine Society guideline and AUA guideline together recommend the following panel before initiating therapy:

Hormonal: Total testosterone (LC-MS/MS preferred), free testosterone (equilibrium dialysis or calculated), LH, FSH, estradiol, prolactin, SHBG.

Hematologic: Complete blood count with hematocrit. Men with baseline hematocrit above 50% are at higher risk of crossing the 54% safety ceiling on therapy.

Metabolic: Fasting glucose or HbA1c, lipid panel, comprehensive metabolic panel (including creatinine and ALT/AST). The Testosterone Trials (TTrials) enrolled 790 men aged 65 and older and found that men with baseline HbA1c above 5.7% showed larger improvements in insulin sensitivity on TRT, making this value clinically informative for goal-setting.

Prostate: PSA and digital rectal exam. Men with PSA above 4.0 ng/mL (or above 3.0 ng/mL in high-risk populations) need urology evaluation before starting TRT.

Bone: DEXA scan if the patient has a history of low-trauma fracture, glucocorticoid use, or BMI <20. The TTrials bone substudy showed TRT increased lumbar spine BMD by 6.1% at 12 months compared to 0.3% with placebo, so having a baseline DEXA allows you to quantify response.

Cardiovascular screen: Blood pressure, resting heart rate, and an assessment of cardiovascular risk using the ACC/AHA pooled cohort equations. The TRAVERSE trial (N=5,246) demonstrated that TRT did not increase major adverse cardiovascular events versus placebo in men aged 45 to 80 with established or high cardiovascular risk (HR 0.99, 95% CI 0.81 to 1.21), but baseline risk stratification remains standard practice.

The 3-Month Check: First Critical Window

Three months after initiating TRT is the single most important follow-up visit. Draw labs as a trough level (for injectable testosterone cypionate, this means the morning before the next scheduled injection; for topical gel, any morning between 2 and 8 hours after application). The required panel at this visit is focused and specific:

Total testosterone (trough). Target: 400 to 700 ng/dL. If the trough falls below 400, the dose is too low. If it exceeds 700 at trough, the dose is too high or injection frequency needs adjustment [1].

Hematocrit. This is the primary safety analyte. The Endocrine Society states: "If hematocrit is above 54%, stop testosterone therapy until hematocrit decreases to a safe level; evaluate the patient for hypoxia and sleep apnea; reinitiate therapy with a reduced dose." A meta-analysis of 35 RCTs (N=5,048) found TRT increased hematocrit by a weighted mean of 2.8 percentage points, with injectable formulations producing larger increases than transdermal preparations.

PSA. A rise of more than 1.4 ng/mL over baseline within 12 months, or any value above 4.0 ng/mL, warrants referral to urology per the AUA guideline.

Symptom assessment. qADAM score or structured clinical interview. If testosterone is in range but symptoms persist, evaluate for comorbid depression, sleep apnea, or thyroid dysfunction.

The 6-to-12-Month Evaluation: Expanding the Safety Net

Between 6 and 12 months, the monitoring scope widens. The testosterone level should be rechecked along with a repeat hematocrit and PSA. This visit adds several analytes that do not need 3-month frequency:

Lipid panel. TRT has variable effects on lipids. The TRAVERSE trial showed modest reductions in HDL cholesterol (approximately 2 mg/dL) without significant changes in LDL or triglycerides over a median 33-month follow-up. Clinicians should compare to baseline and adjust statin therapy if needed.

Metabolic panel. Recheck fasting glucose or HbA1c. The T4DM trial (N=1,007) demonstrated that testosterone treatment combined with lifestyle intervention reduced the 2-year incidence of type 2 diabetes by 40% compared to placebo plus lifestyle (HR 0.59, 95% CI 0.43 to 0.80).

Hepatic function. ALT and AST. Oral testosterone undecanoate (Jatenzo) carries a specific FDA warning regarding hepatotoxicity, though injectable and transdermal formulations rarely affect liver enzymes at replacement doses.

Estradiol. If the patient reports gynecomastia, nipple tenderness, or excessive water retention, check estradiol. The Endocrine Society does not recommend routine aromatase inhibitor use but notes that estradiol above 40 to 50 pg/mL with symptoms may warrant dose adjustment or switching from injectable to transdermal formulation, which produces less aromatization.

Bone density. If a baseline DEXA was obtained, repeat at 1 to 2 years. The TTrials bone study showed that the BMD gains with TRT were concentrated in the spine (6.1%) and hip (1.2%), with trabecular bone responding more than cortical bone.

Annual Monitoring: The Indefinite Maintenance Phase

After the first year, the Endocrine Society recommends annual follow-up with the following panel:

Total testosterone trough, hematocrit, PSA, lipid panel, fasting glucose or HbA1c, comprehensive metabolic panel. Blood pressure should be checked at every visit. The digital rectal exam is recommended annually for men over 40, though the USPSTF notes that shared decision-making about PSA-based prostate cancer screening applies equally to men on TRT.

Bone density via DEXA should continue every 1 to 2 years in men with osteopenia or osteoporosis at baseline. For men with normal baseline BMD, repeat DEXA is not required unless new risk factors emerge (glucocorticoid use, significant weight loss, fragility fracture).

Semen analysis is relevant only if fertility is a concern. TRT suppresses spermatogenesis in most men within 3 to 6 months. The Endocrine Society explicitly states that testosterone should not be used in men who are actively trying to conceive. Alternatives such as clomiphene citrate, human chorionic gonadotropin (hCG), or selective estrogen receptor modulators should be offered instead.

Monitoring by Formulation: Timing Differences That Change the Schedule

Not every testosterone formulation has the same pharmacokinetics, and monitoring timing must match the delivery system.

Testosterone cypionate or enanthate (IM/SubQ, every 1 to 2 weeks). Draw trough levels the morning of the next injection. Peak-trough swings can be large, with peaks reaching 900 to 1,200 ng/dL and troughs dropping to 300 to 400 ng/dL on biweekly dosing. The Endocrine Society recommends weekly or twice-weekly injections to reduce these fluctuations.

Testosterone gel 1% or 1.62% (daily application). Steady-state is reached by day 30. Draw levels 2 to 8 hours after application. Transfer risk (to female partners or children) requires a specific counseling note in the chart at baseline.

Testosterone undecanoate (Aveed, IM every 10 weeks). Measure trough just before the next injection. The FDA requires a REMS program for this formulation due to risk of pulmonary oil microembolism and anaphylaxis, mandating 30-minute post-injection observation at each visit.

Testosterone pellets (SubQ, every 3 to 6 months). Levels peak at 4 to 6 weeks and decline linearly. Draw mid-cycle (8 to 10 weeks post-insertion) and at trough (just before reinsertion).

Oral testosterone undecanoate (Jatenzo, twice daily with food). Draw levels 3 to 5 hours after the morning dose with a fatty meal. This formulation has the highest intraindividual variability, and clinicians should average two or three measurements before adjusting dose.

Red Flags That Trigger Unscheduled Testing

Certain symptoms or findings should prompt immediate lab work outside the regular schedule. The Endocrine Society and AUA guidelines converge on these indications:

New or worsening lower urinary tract symptoms (LUTS). Check PSA, consider urology referral, and perform uroflowmetry. The TRAVERSE trial prostate substudy found a small increase in prostate biopsy rates in the TRT arm (6.7% vs. 5.0%) but no significant difference in prostate cancer incidence.

Leg swelling, dyspnea, or chest pain. Check hematocrit urgently. If above 54%, hold TRT and consider therapeutic phlebotomy. Evaluate for deep vein thrombosis or pulmonary embolism. The FDA added a general warning about venous thromboembolism (VTE) to all testosterone product labels in 2014, though the TRAVERSE trial did not confirm an excess VTE risk (HR 1.03, 95% CI 0.68 to 1.57).

Mood changes, irritability, or aggressive behavior. Recheck total testosterone; supra-physiologic levels (above 1,000 ng/dL at trough) can cause mood disturbance. Reduce dose and recheck in 4 to 6 weeks.

Breast tenderness or gynecomastia. Check estradiol and prolactin. Reduce dose or switch formulation before considering an aromatase inhibitor.

Sleep apnea onset or worsening. TRT can exacerbate obstructive sleep apnea. The Endocrine Society recommends polysomnography if symptoms emerge, and dose reduction or cessation if severe apnea is confirmed.

Putting It Together: A Printable Timeline

Pre-TRT (Day 0): Two confirmatory morning total T draws, free T, LH, FSH, prolactin, estradiol, SHBG, CBC, CMP, lipids, HbA1c, PSA, DRE, DEXA (if indicated), cardiovascular risk assessment, sleep apnea screening.

Month 3: Total T (trough), hematocrit, PSA, symptom questionnaire (qADAM).

Month 6: Total T (trough), hematocrit, PSA, lipids, HbA1c, estradiol (if symptomatic), hepatic panel.

Month 12: Full panel repeat (total T, CBC, CMP, lipids, HbA1c, PSA, DRE), DEXA if baseline was abnormal, symptom questionnaire.

Annually thereafter: Total T (trough), CBC, CMP, lipids, HbA1c, PSA, DRE, blood pressure, symptom assessment. DEXA every 1 to 2 years if osteopenia or osteoporosis was present at baseline.

Men with hematocrit above 50% at baseline, a history of VTE, or untreated sleep apnea require more frequent monitoring (every 6 to 8 weeks initially) until values stabilize. The target testosterone trough for most men is 400 to 700 ng/dL, and dose titration at 3-month intervals continues until that range is reached with symptom resolution [1].